ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Drug toxicity"

  • Abstract Number: 0777 • ACR Convergence 2022

    Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study

    Arjun Raghavan1, Liam O'Neil1, Carrie Ye2 and Jeffrey Graham1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: The advent of immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer. Patients with pre-existing autoimmune diseases (AID) were largely excluded from…
  • Abstract Number: 0816 • ACR Convergence 2022

    Increased Risk of Hepatotoxicity with DMARDS in Patients with Previous Liver Toxicity with Isoniazid: Study in a Single University Hospital

    David Martínez-López1, Joy Osorio-Chávez1, Virgi Portilla2, Carmen Alvarez Reguera1, Alba Herrero-Morant3, Lara Sánchez-Bilbao1, iñigo Gonzalez-Mazon1, Miguel Ángel González-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 4Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Isoniazid (INH) is used to treat latent tuberculosis infection (LTBI), and hepatotoxicity is one of the most frequent adverse effect. Several Disease-modifying drugs (DMARDs)…
  • Abstract Number: 0929 • ACR Convergence 2022

    Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases

    Cara Kumar1, Kristine Herrmann1 and Martin Aringer2, 1Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany

    Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…
  • Abstract Number: 0930 • ACR Convergence 2022

    Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation

    Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
  • Abstract Number: 0980 • ACR Convergence 2022

    The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc

    Kourtney Rudzinski1, Zaina Shahid2, Yasin kanakrieh2, Saloni Goyal2, Kyle Shaak2 and James Ross3, 1Lehigh Valley Health Network, Tatamy, PA, 2Lehigh Valley Health Network, Allentown, PA, 3lvhn, Macungie, PA

    Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…
  • Abstract Number: 1076 • ACR Convergence 2022

    ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain

    Naomi Patel1, David Jayne2, Peter Merkel3, Pirow Bekker4, yuqing zhang5, Huibin Yue4 and John Stone6, 1Massachusetts General Hospital, Sale Creek, TN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4ChemoCentryx, San Juan Capistrano, CA, 5Massachusetts General Hospital, Quincy, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
  • Abstract Number: 1081 • ACR Convergence 2022

    Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide

    Elizabeth Nettleton1, Sebastian Sattui2, Zachary Wallace3 and Mike Putman1, 1The Medical College of Wisconsin, Milwaukee, WI, 2University of Pittsburgh, Pittsburgh, PA, 3Massachusetts General Hospital, Boston, MA

    Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
  • Abstract Number: 0288 • ACR Convergence 2022

    Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study

    Loïc Meudec1, Pauline Richebé1, Juliette Pascaud2, Xavier Mariette3 and Gaetane Nocturne4, 1Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, 2Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, 3Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 4APHP, Le Kremlin Bicêtre, France

    Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
  • Abstract Number: 1108 • ACR Convergence 2022

    Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis

    Danielle Stahlbaum1, Renea Jablonski1, Mary Strek2 and Pankti Reid1, 1University of Chicago Medical Center, Chicago, IL, 2University of Chicago, Chicago, IL

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
  • Abstract Number: 0291 • ACR Convergence 2022

    Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients

    Naga Prabu1, velammal petchaippan2, Gayathri anand3, Aswathi kumar1 and Saranya Ramachandiran3, 1SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, 2PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, 3sakthi rheumatology centre pvt l;td, Coimbatore, India

    Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
  • Abstract Number: 1131 • ACR Convergence 2022

    Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine

    Puran Nepal, Jacy Zanussi, Alyson Dickson, Laura Daniel, Tyne Miller-Fleming, Peter Straub, Adriana Hung, Wei-Qi Wei, Nancy Cox, Michael Stein, QiPing Feng and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Azathioprine is used to treat several autoimmune conditions, but its use is limited by side effects. Leukopenia, a severe, potentially life-threatening side effect is…
  • Abstract Number: 0345 • ACR Convergence 2022

    Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis

    Alba Herrero-Morant1, Jon Zubiaur-Zamacola2, Adrián Margarida-De Castro2, Raquel Pérez-Barquín2, Miguel Ángel González-Gay3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
  • Abstract Number: 1133 • ACR Convergence 2022

    Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus

    Cecilia Chung, Gul Karakoc, Jorge Gamboa, Jonathan Mosley, Nancy Cox, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white…
  • Abstract Number: 0436 • ACR Convergence 2022

    Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

    Julien Culerrier1, Yann Nguyen2, Omer Karadag3, Sule Yasar Bilge4, Tuba DEMIRCI YILDIRIM5, Tahir Saygin Öğüt6, Veli Yazisiz6, Cemal Bes7, Ayse Cefle8, Oznur Sadioglu Cagdas9, Ayten Yazici8, Andreas Kronbichler10, David Jayne10, Alexis Regent11, Vitor Teixeira12, Sylvain Marchand-Adam13, PIerre Duffau14, Saskia Oro15, Baptiste Andre16, Luminita Luca17, Sarah Lechtman18, Achille Aouba19, Celine Lebas20, Amélie Servettaz21, Amandine Dernoncourt22, Marc Ruivard23, Anne-Marie Milesi24, Vincent Poindron25, Patrick Jego26, Roberto Padoan27, Paolo Delvino28, Frédéric Vandergheynst29, Christian Pagnoux30, Elaine Yacyshyn31, Peter Lamprecht32, Oliver Flossmann33, Xavier Puéchal11 and Benjamin Terrier11, 1Université Paris Cité, Paris, France, Paris, France, 2AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 3Hacettepe University, Ankara, Turkey, 4Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, 5Dokuz Eylul University, İzmir, Turkey, 6Akdeniz University, Antalya, Turkey, 7Bahçeşehi University, Istanbul, Turkey, 8Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 9Kocaeli University, Kocaeli, Turkey, 10University of Cambridge, Cambridge, United Kingdom, 11National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 12Hospital de Faro, CHUA, Lisbon, Portugal, 13Tours University Hospital, Tours, France, 14CHU Bordeaux, Bordeaux, France, 15Assistance Publique - Hôpitaux de Paris., Paris, France, 16Hôpital de la Timone, Marseille, Marseille, France, 17CHU de Poitiers, Poitiers, France, 18CHU Nice, Nice, France, 19Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 20CHRU Lille, Lille, France, 21CHU Reims, Reims, France, 22CHU Amiens - Picardie, Amiens, France, 23Clermont Ferrand University Hospital, Clermont-Ferrand, France, 24Centre hospitalier de Vichy, Vichy, France, 25Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26CHU Rennes, Paris, France, 27University of Padova, Padova, Italy, 28Università di Pavia, Vercelli, Italy, 29Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, 30Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 31University of Alberta, Edmonton, AB, Canada, 32Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, 33Royal Berkshire Hospital, Reading, United Kingdom

    Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
  • Abstract Number: 1134 • ACR Convergence 2022

    Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine

    Jacy Zanussi, Puran Nepal, Alyson Dickson, Laura Daniel, Peter Straub, Tyne Miller-Fleming, Wei-Qi Wei, Adriana Hung, Nancy Cox, Vivian Kawai, Jonathan Mosley, Michael Stein, QiPing Feng, Ge Liu, Ran Tao and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Azathioprine is a thiopurine drug used for the treatment of several inflammatory and autoimmune conditions. However, its use is limited due to side effects,…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences